An observational study in Chronic Rhinosinusitis (Diagnosis) and Cystic Fibrosis, sponsored by University of California, Los Angeles. Recruiting at 9 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by University of California, Los Angeles · Observational
Among 716 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 110 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 716 studies in Cystic Fibrosis with a site in United States, this one is the 56th largest by planned enrollment of the 193 observational ones, is one of 34 that started in 2020, is one of 194 observational ones, reaches primary completion later than 39 of the 107 other live ones, and was the 548th registered.
1,619 studies on the registry are indexed under Cystic Fibrosis; 199 are open to participants now.
This study's planned enrollment of 170 is above the median of 85 across 503 observational studies indexed under Cystic Fibrosis.
Browse Cystic Fibrosis studies →85 of the 716 studies in Cystic Fibrosis with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 154 Cystic Fibrosis studies recruiting now, 95 (62%) set no upper age limit and 43 (28%) stop at 75 or younger; 84 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →716 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 34 started in 2020.
Median enrollment 36 across the 516 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
250 of 716 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 2 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Among the 716 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do not undergo surgery but are treated medically for CRS will also be enrolled to serve as a control group. Outcomes analyzed will include pulmonary, quality of life, and others.
1,619 studies on the registry are indexed under Cystic Fibrosis; 199 are open to participants now.
This study's planned enrollment of 170 is above the median of 85 across 503 observational studies indexed under Cystic Fibrosis.
Browse Cystic Fibrosis studies →University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
Compared within Cystic Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Subjects will be recruited from cystic fibrosis and otolaryngology outpatient clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals with cystic fibrosis and chronic rhinosinusitis who undergo endoscopic sinus surgery
Individuals with cystic fibrosis and chronic rhinosinusitis who do not undergo endoscopic sinus surgery
Change in pulmonary function
Pulmonary function will be measured using spirometry - the percent of predicted forced expiratory volume in the first second (ppFEV1)
Time frame: baseline, 3, 6, 9, 12 months
Change in days of inpatient hospitalization
Days of inpatient hospitalization will be assessed
Time frame: baseline, 3, 6, 9, 12 months
Change in quality of life
Quality of life will be assessed using the 22-question SinoNasal Outcome test (range 0-110, with higher scores signifying worse quality of life)
Time frame: baseline, 3, 6, 9, 12 months
Change in quality of life
Quality of life will be assessed using the Cystic Fibrosis Questionnaire-Revised instrument (range 0-100, with higher scores signifying worse quality of life)
Time frame: baseline, 3, 6, 9, 12 months
Change in olfaction
Olfaction will be assessed using the Smell Identification Test (score range: 0-40, with higher scores demonstrated better olfactory ability)
Time frame: baseline, 3, 6, 9, 12 months
Patient satisfaction regarding treatment for chronic rhinosinusitis
Satisfaction will be assessed using 5-point Likert scales, ranging from 1 to 5 with 1 signifying "not important" and 5 signifying "very important"
Time frame: at baseline
Plan to share: No — Participant data will securely stored using REDCap software.
Started Jul 2020 (actual). Primary completion is estimated for Jan 2027, 78 months after the start.
Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 78 months is above that.
Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →